Hir­ing? How End­points can help your com­pa­ny fill open po­si­tions with our tal­ent­ed read­ers

We’ve just launched End­points Ca­reers, our new prod­uct con­nect­ing em­ploy­ers and job­seek­ers. The com­pe­ti­tion for bio­phar­ma tal­ent is fierce, and giv­en the unique place End­points News has in the in­dus­try, we think our ap­proach has a few key ad­van­tages that make this a com­pelling of­fer and not just an­oth­er “job board.”

The first rea­son is that we’re an­chor­ing it to En­ter­prise, our $1,000/year paid sub­scrip­tion plan for com­pa­nies of all sizes. You can think of En­ter­prise as the “com­plete” ver­sion of End­points News. No mat­ter how large or small the com­pa­ny is, that one price un­locks pay­wall con­tent for every em­ploy­ee. No seat li­cens­es or vol­ume pric­ing. We want to make this pro­gram an easy de­ci­sion at every com­pa­ny with an in­ter­est in the bio­phar­ma world. Sev­er­al hun­dred have al­ready joined En­ter­prise, and now with End­points Ca­reers, we want to make it even more ben­e­fi­cial to join.

Start­ing to­day, we’re in­tro­duc­ing a new ben­e­fit for En­ter­prise sub­scribers: Two Fea­tured Job List­ings per year on End­points Ca­reers — an $800 val­ue. If you’re a hir­ing man­ag­er at a com­pa­ny with a valid En­ter­prise sub­scrip­tion, you have two fea­tured job post­ings wait­ing for you to re­deem — just con­tact Tom Kowal­sky tom@end­pointsnews.com on our team to get start­ed. And once you do, the list­ings will be dis­trib­uted across the en­tire End­points net­work: email, web, and so­cial. Again: we’re sell­ing the same pack­age for $800 for com­pa­nies who aren’t part of the En­ter­prise pro­gram.

The oth­er key ad­van­tage on End­points Ca­reers is our fo­cus on qual­i­ty, not quan­ti­ty.

Most “job boards” be­gin with thou­sands of job list­ings pre-filled, in an at­tempt to look busy and gain web traf­fic. We take the op­po­site view. We on­ly want re­cent jobs with the high­est rel­e­vance to our au­di­ence base. And giv­en the big traf­fic num­bers to End­points News and our re­lat­ed dis­tri­b­u­tion chan­nels, we’re able to ad­ver­tise these po­si­tions in a very ef­fec­tive way: Job seek­ers are as­sured of see­ing on­ly the high­est qual­i­ty list­ings from em­ploy­ers, while em­ploy­ers get wide air cov­er­age for their open po­si­tions with­in the elite End­points read­er­ship.

We de­signed it this way. Bio­phar­ma tends to be an in­su­lar crowd with an es­pe­cial­ly big pre­mi­um placed on re­fer­rals from in­side a net­work — which is no sur­prise in an in­dus­try that is as heav­i­ly reg­u­lat­ed and sci­ence-based as this one is. In­sti­tu­tion­al knowl­edge is held by peo­ple, not in com­pa­ny clouds or lab notes. And the net­work ef­fects gained from re­cruit­ing the right kind of ex­pe­ri­enced tal­ent who know the right peo­ple are too valu­able to be mea­sured in dol­lars. This won’t ever change. It’s a sto­ry we chron­i­cle in End­points about every com­pa­ny with am­bi­tion, time and time again.

But re­fer­rals do have their lim­its. Was the job op­por­tu­ni­ty ex­posed to the most di­verse tal­ent pool pos­si­ble? How does a found­ing team of a few fa­mil­iar faces re­cruit a work­force that can bring fresh ideas and ap­proach­es?

Ba­si­cal­ly: Did we cast a wide enough net?

End­points Ca­reers is here to help solve this is­sue: ad­ver­tis­ing bio­phar­ma op­por­tu­ni­ties with­in an elite net­work, and do­ing so on a scale that ex­pos­es it to the broad­est au­di­ence pos­si­ble.

We think that’s a com­pelling of­fer that con­tin­ues to dif­fer­en­ti­ate End­points and how we serve our read­ers. End­points Ca­reers will on­ly con­tin­ue to grow through­out the year as we in­te­grate it with our week­ly Peer Re­view col­umn. If you have any ques­tions or want to get start­ed with End­points Ca­reers, we’ve brought Tom tom@end­pointsnews.comon board as a ded­i­cat­ed client man­ag­er to help, and you can al­ways con­tact me di­rect­ly as well. So please check out End­points Ca­reers — we’re very ex­cit­ed to bring it to you.

– Ar­salan Arif
Founder & CEO, End­points News
aa@end­pointsnews.com

How one start­up fore­told the neu­ro­science re­nais­sance af­ter '50 years of shit­show'

In the past couple of years, something curious has happened: Pharma and VC dollars started gushing into neuroscience research.

Biogen’s controversial new Alzheimer’s drug Aduhelm has been approved on the basis of removing amyloid plaque from the brain, but the new neuro-focused pharma and biotechs have much loftier aims. Significantly curbing or even curing the most notorious disorders would prove the Holy Grail for a complex system that has tied the world’s best drug developers in knots for decades.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Ryan Watts, Denali CEO

De­nali slips as a snap­shot of ear­ly da­ta rais­es some trou­bling ques­tions on its pi­o­neer­ing blood-brain bar­ri­er neu­ro work

Denali Therapeutics had drummed up considerable hype for their blood-brain barrier technology since launching over six years ago, hype that’s only intensified in the last 14 months following the publications of a pair of papers last spring and proof of concept data earlier this year. On Sunday, the South San Francisco-based biotech gave the biopharma world the next look at in-human data for its lead candidate in Hunter syndrome.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,800+ biopharma pros reading Endpoints daily — and it's free.

Why is On­col­o­gy Drug De­vel­op­ment Re­search Late to the Dig­i­tal Bio­mark­ers Game?

During the recent Annual ASCO Meeting, thousands of cancer researchers and clinicians from across the globe joined together virtually to present and discuss the latest findings and breakthroughs in cancer research and care. There were more than 5000+ scientific abstracts presented during this event, yet only a handful involved the use of motion-tracking wearables to collect digital measures relating to activity, sleep, mobility, functional status, and/or quality of life. Although these results were a bit disappointing, they should come as no surprise to those of us in the wearable technology field.

Art Levinson (Calico)

Google-backed Cal­i­co dou­bles down on an­ti-ag­ing R&D pact with Ab­b­Vie as part­ners ante up $1B, start to de­tail drug tar­gets

Seven years after striking up a major R&D alliance, AbbVie and Google-backed anti-aging specialist Calico are doubling down on their work with a joint, $1 billion commitment to continuing their work together. And they’re also beginning to offer some details on where this project is taking them in the clinic.

According to their statement, each of the two players is putting up $500 million more to keep the labs humming.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,800+ biopharma pros reading Endpoints daily — and it's free.

Busi­ness­es and schools can man­date the use of Covid-19 vac­cines un­der EUAs, DOJ says

As public and private companies stare down the reality of the Delta variant, many are now requiring that their employees or students be vaccinated against Covid-19 prior to attending school or to returning or starting a new job. Claims that such mandates are illegal or cannot be used for vaccines under emergency use authorizations have now been dismissed.

Setting the record straight, the Department of Justice on Monday called the mandates legal in a new memo, even when used for people with vaccines that remain subject to EUAs.

Ugur Sahin, BioNTech CEO (Bernd von Jutrczenka/dpa via AP Images)

BioN­Tech is spear­head­ing an mR­NA vac­cine de­vel­op­ment pro­gram for malar­ia, with a tech trans­fer planned for Africa

Flush with the success of its mRNA Covid-19 vaccine, BioNTech is now gearing up for one of the biggest challenges in vaccine development — which comes without potential profit.

The German mRNA pioneer says it plans to work on a jab for malaria, then transfer the tech to the African continent, where it will work with partners on developing the manufacturing ops needed to make this and other vaccines.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,800+ biopharma pros reading Endpoints daily — and it's free.

Andrea Pfeifer, AC Immune CEO (AC Immune)

Look­ing to repli­cate Covid-19 suc­cess in neu­ro, BioN­Tech back­ers bet on AC Im­mune and its new­ly-ac­quired Parkin­son's vac­cine

The German billionaires behind BioNTech have found a new vaccine project to back.

Through their family office Athos Service, twin brothers Thomas and Andreas Strüngmann are leading a $25 million private placement into Switzerland’s AC Immune — which concurrently announced that it’s shelling out $58.7 million worth of stock to acquire Affiris’ portfolio of therapies targeting alpha-synuclein, including a vaccine candidate, for Parkinson’s disease.

Mer­ck­'s wom­en's health spin­out snags mid-stage can­di­date for preterm birth; Keytru­da nails down TNBC ap­proval af­ter March CRL

Nearly two months after spinning out from Merck, women’s health business Organon has struck its first half-billion-dollar deal.

Organon $OGN has promised $25 million upfront and another $475 million in biobucks for worldwide rights to ebopiprant, ObsEva’s investigational treatment for preterm labor. Ebopiprant, a selective prostaglandin F2α (PGF2α) receptor antagonist, was originally licensed from Merck KGaA in 2015. The candidate works by reducing inflammation and uterine contractions.

No­var­tis reshuf­fles its wild cards; Tough sell for Bio­gen? Googling pro­teins; Ken Fra­zier's new gig; and more

Welcome back to Endpoints Weekly, your review of the week’s top biopharma headlines. Want this in your inbox every Saturday morning? Current Endpoints readers can visit their reader profile to add Endpoints Weekly. New to Endpoints? Sign up here.

If you enjoy the People section in this report, you may also want to check out Peer Review, my colleagues Alex Hoffman and Kathy Wong’s comprehensive compilation of comings and goings in biopharma.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 112,800+ biopharma pros reading Endpoints daily — and it's free.